FOXO3

FOXO3 is a forkhead transcription factor that links survival-factor signaling to apoptosis, oxidative-stress control, cell-cycle restraint, and homeostasis^[1][2]. Mechanistically, Akt phosphorylates FOXO3/FKHRL1, promotes 14-3-3 association, retains it in the cytoplasm, and suppresses target-gene activation, whereas survival-factor withdrawal drives nuclear FOXO3 activity^[1]. In quiescent cells, FOXO3a protects against oxidative stress by increasing MnSOD mRNA and protein, thereby limiting reactive oxygen species-linked apoptosis^[2]. In mice, Foxo3 deficiency disrupts oxidative-stress regulation, erythroid maturation, cell-cycle control, and erythrocyte lifespan during erythropoiesis^[3]. Compared with related FOXO isoforms, FOXO3 research requires isoform-aware design because FOXO family proteins show differential roles across homeostasis, stem-cell maintenance, cancer, metabolic disease, and cardiovascular disease^[4]. A focused model identified Foxo3 isoform 2 as an N-terminal-truncated form that suppresses osteoclastogenesis through type I IFN response genes and endogenous IFN-β feedback during RANKL stimulation^[5]. For experimental applications, carbenoxolone was identified as a FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma^[6]. Small DBD-binding compounds S9 and S9OX interfere with FOXO3 target-promoter binding and gene transcription, supporting use of DNA-binding-domain modulation in FOXO3 pathway studies^[7].